Lexogen Receives FFG Funding to Develop a Novel SARS-CoV-2 Test for Mass Screening
04/29/20, 1:17 PM
Location
viennaLexogen GmbH, a Vienna based Next-Generation Sequencing (NGS) and transcriptomics company, receives funding from the Austria Research Promotion Agency (FFG) for the development of a novel SARS-CoV-2 test method for mass screening.
Company Info
Location
vienna, illinois, united states
Additional Info
Established in 2007, Lexogen is a transcriptomics and Next-Generation Sequencing company, focusing on the development of innovative methods for RNA analysis. Its portfolio includes multiple innovative and well-established protocols for RNA sequencing sample preparation, external RNA spike-in controls, as well as bioinformatics tools and sequencing services. Lexogen is a privately held company, headquartered in Vienna, Austria with a subsidiary in New Hampshire, US.For more information about Lexogen visit www.lexogen.com and follow @lexogen.